Odyssey Therapeutics, Inc. (ODTX)
Nasdaq · Biological Products, (No Diagnostic Substances) · Manufacturing · CIK 1882782 · fiscal year ends in Dec
Closing price $19.55 on 30 Oct 2026; 52-week range $15.56 to $28.76.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $936.3M
- Cash
- $82.0M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 47.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $0 | -$52.8M | -$1.74 |
| Q1 FY2026 | 31 Mar 2026 | $0 | -$38.3M | -$6.77 |
| Q2 FY2025 | 30 Jun 2025 | $959.0K | -$41.2M | -$29.54 |
| Q1 FY2025 | 31 Mar 2025 | $1.9M | -$38.4M | -$39.37 |
Company events
The newest 8-K filings of 6 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 20 Oct 2026 | 8-K | Investor update | 7.01, 9.01 |
| 9 Sep 2026 | 8-K | Investor update | 7.01, 9.01 |
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 17 Jun 2026 | 8-K | Results | 2.02, 9.01 |
| 11 May 2026 | 8-K | Material agreement, Share sale, Bylaws or fiscal year change | 1.01, 3.02, 5.03, 9.01 |
Every filing
The newest filings with the SEC of 28 held.
| Filed | Form | Period |
|---|---|---|
| 20 Oct 2026 | 8-K | 20 Oct 2026 |
| 9 Sep 2026 | 8-K | 8 Sep 2026 |
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 23 Jun 2026 | 8-K | 23 Jun 2026 |
| 17 Jun 2026 | 10-Q | 31 Mar 2026 |
| 17 Jun 2026 | 8-K | 17 Jun 2026 |
| 11 May 2026 | 8-K | 7 May 2026 |
| 11 May 2026 | S-8 | – |
| 7 May 2026 | EFFECT | – |
| 7 May 2026 | S-1MEF | – |
| 7 May 2026 | CERT | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 May 2026 | Tpg Gp A, Llc, Insider | Purchase | 1,388,889 | $18.00 | $25.0M | 3,690,146 | 13 May 2026 |
| 8 May 2026 | Dimension Capital Ii, L.P., Director | Purchase | 1,111,111 | $18.00 | $20.0M | 3,333,516 | 12 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Sale outside a trading plan | 1,065 | $18.00 | $19.2K | 1,609,161 | 11 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Purchase | 222,222 | $18.00 | $4.0M | 1,831,383 | 11 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Sale outside a trading plan | 277 | $18.00 | $5.0K | 440,981 | 11 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Purchase | 133,333 | $18.00 | $2.4M | 574,314 | 11 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Sale outside a trading plan | 438 | $18.00 | $7.9K | 814,851 | 11 May 2026 |
| 11 May 2026 | Sr One Capital Management, Llc, 10% owner | Purchase | 200,000 | $18.00 | $3.6M | 1,014,851 | 11 May 2026 |
| 11 May 2026 | Li Nan (Ln), Director | Purchase | 1,111,111 | $18.00 | $20.0M | 3,333,516 | 11 May 2026 |
| 11 May 2026 | Chu Shelley, Director | Purchase | 11,111 | $18.00 | $200.0K | 11,111 | 11 May 2026 |
| 8 May 2026 | Leiden Jeffrey M, Director | Purchase | 5,000 | $20.00 | $100.0K | 270,198 | 11 May 2026 |
| 8 May 2026 | Haas Jason, Chief Financial Officer | Purchase | 1,000 | $20.00 | $20.0K | 62,908 | 11 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 5 Jun 2026 | FMR LLC | 13G | 10.2% | 4.6M |
| 18 May 2026 | Lightspeed Venture Partners XV-B (Ignite), L.P. | 13G | 7.6% | 3.6M |
| 18 May 2026 | TPG GP A, LLC | 13D | 7.8% | 3.7M |
| 18 May 2026 | SR One Capital Management, LLC | 13D | 8% | 3.8M |
| 15 May 2026 | Dimension Management, L.P. | 13D | 7.1% | 3.3M |
| 15 May 2026 | Jeito II S.L.P. | 13D | 7.8% | 3.7M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.3M | +5.68% | 12.38 |
| 30 Sep 2026 | 3.1M | +40.6% | 5.63 |
| 15 Sep 2026 | 2.2M | -0.01% | 10.78 |
| 31 Aug 2026 | 2.2M | -1.8% | 12.81 |
| 14 Aug 2026 | 2.2M | -0.95% | 18.66 |
| 31 Jul 2026 | 2.3M | +13.9% | 9.68 |
| 15 Jul 2026 | 2.0M | +10.97% | 6.51 |
| 30 Jun 2026 | 1.8M | +33.75% | 3.68 |
Funds that hold it
From each fund's latest Form 13F.
59 funds held it at 30 Jun 2026: 59 added and 0 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| FMR LLC | 5,179,262 | $96.9M | +5,179,262 |
| SR One Capital Management, LP | 3,794,883 | $71.0M | +3,794,883 |
| TPG GP A, LLC | 3,690,146 | $69.0M | +3,690,146 |
| Lightspeed Management Company, L.l.c. | 3,608,443 | $67.5M | +3,608,443 |
| Orbimed Advisors LLC | 3,001,198 | $56.2M | +3,001,198 |
| Sanofi | 1,991,918 | $37.3M | +1,991,918 |
| Deerfield Management Company, L.P. | 1,046,139 | $19.6M | +1,046,139 |
| Sands Capital Alternatives, LLC | 875,000 | $16.4M | +875,000 |
| Hhlr Advisors, Ltd | 831,656 | $15.6M | +831,656 |
| General Catalyst Group Management, LLC | 810,272 | $15.2M | +810,272 |
Peers
Companies in the same industry.
- Amgen Inc. (AMGN): revenue $38.1B, market value $252.0B
- Gilead Sciences, Inc. (GILD): revenue $31.0B, market value $212.0B
- Moderna, Inc. (MRNA): revenue $2.2B, market value $88.5B
- argenx SE (ARGX): revenue $4.2B, market value $55.3B
- Biogen Inc. (BIIB): revenue $10.3B, market value $37.5B
- BioNTech SE (BNTX): revenue $3.2B, market value $22.1B
- Exelixis, Inc. (EXEL): revenue $2.5B, market value $17.0B
- Halozyme Therapeutics, Inc. (HALO): revenue $1.7B, market value $14.9B
- Neurocrine Biosciences Inc. (NBIX): revenue $3.4B, market value $14.9B
- Bio-Techne Corp. (TECH): revenue $1.2B, market value $11.3B